Merional
Phase 3Small molecule
Merional is one of 76 small molecule programs targeting Endometriosis. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
199 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Orilissa
AbbViePhase 3
Revia
TevaPhase 3
Orgovyx
Sumitomo Pharma America, Inc.Phase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
EE20/DRSP(BAY86-5300)
BayerPhase 3
Triptorelin Embonate
IpsenPhase 3
Add-Back
KKissei Pharmaceutical Co., Ltd.
Phase 3
Visanne
BayerPhase 3
Triptorelin Acetate PR 1-Month
IpsenPhase 3
Merional
CCairo University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Infertility2 trials
Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Couples With Mild Male Factor Infertility
Unknown status·—·Phase 3·NCT02469805·450 enrolled
Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility
Unknown status·—·Phase 3·NCT02461173·450 enrolled
Endometriosis1 trial
Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis
Unknown status·—·Phase 3·NCT02470169·450 enrolled
Ovulation Induction1 trial
The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS
Unknown status·—··NCT02673632·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Merional. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCairo University